Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This combination dietary supplement regimen, investigated by the University of California, San Diego, consists of betaine, creatine, Metafolin (L-5-methyltetrahydrofolate), and vitamin B12. It was developed as a pro-methylation strategy for the treatment of Angelman syndrome, a genetic disorder characterized by the loss of UBE3A gene expression from the maternal chromosome. The regimen aimed to promote DNA methylation at the UBE3A locus to silence the antisense transcript and reactivate the expression of the paternal UBE3A gene. Clinical evaluation in a single-arm trial (NCT00348933) involving children under 6 years of age demonstrated that while the combination was safe and well-tolerated, it failed to produce statistically significant improvements in developmental functioning or clinical symptoms.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on betaine + creatine + L-5-methyltetrahydrofolate + vitamin B12.